Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics (ATHE)
:ATHE
ATHE Stock Chart & Stats
$3.55
-$0.16(-4.23%)
At close: 4:00 PM EST
$3.55
-$0.16(-4.23%)
Day’s Range― - ―
52-Week Range$2.20 - $7.00
Previous CloseN/A
Volume131.33K
Average Volume (3M)13.23K
Market Cap
$57.67M
Enterprise Value$44.47M
Total Cash (Recent Filing)$40.66M
Total Debt (Recent Filing)$155.46K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 26, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding18,125,694
10 Day Avg. Volume17,264
30 Day Avg. Volume13,231
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue8.18
Enterprise Value/Gross Profit8.37
Enterprise Value/Ebitda-3.04
Forecast
1Y Price Target
$12.00Price Target Upside238.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$5.31M
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessPresentations at 2025 Movement Disorders Conference strengthen the Phase 2 dataset for ATH434.
Drug EfficacyATH434 demonstrated a beneficial effect on orthostatic hypotension, with stabilization from baseline in both the 50mg and 75mg groups compared to a 6-point decline over 52 weeks for placebo.
Safety And TolerabilityThe drug was well tolerated with no treatment-related serious adverse events.
Bears Say
Alterity Therapeutics News
ATHE FAQ
What was Alterity Therapeutics’s price range in the past 12 months?
Alterity Therapeutics lowest stock price was $2.20 and its highest was $7.00 in the past 12 months.
What is Alterity Therapeutics’s market cap?
Alterity Therapeutics’s market cap is $57.67M.
When is Alterity Therapeutics’s upcoming earnings report date?
Alterity Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 67 days.
How were Alterity Therapeutics’s earnings last quarter?
Alterity Therapeutics released its earnings results on Feb 28, 2025. The company reported -$0.522 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.359.
Is Alterity Therapeutics overvalued?
According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued.
Does Alterity Therapeutics pay dividends?
Alterity Therapeutics does not currently pay dividends.
What is Alterity Therapeutics’s EPS estimate?
Alterity Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Alterity Therapeutics have?
Alterity Therapeutics has 18,125,694 shares outstanding.
What happened to Alterity Therapeutics’s price movement after its last earnings report?
Alterity Therapeutics reported an EPS of -$0.522 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Alterity Therapeutics?
Currently, no hedge funds are holding shares in ATHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (238.03% Upside)
$12.00 (238.03% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
47.14%
12-Months-Change
Fundamentals
Return on Equity
-42.68%
Trailing 12-Months
Asset Growth
134.94%
Trailing 12-Months
Company Description
Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
ATHE Stock 12 Month Forecast
Average Price Target
$12.00
▲(238.03% Upside)
Technical Analysis
Cel-Sci
―
XBiotech
―
Repare Therapeutics
―
Kalaris Therapeutics
―
Unicycive Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---